Combined zidovudine and interferon‐alpha treatment in patients with AIDS‐associated Kaposi's sarcoma

R. de WIT*, S. A. DANNER, P. J.M. BAKKER, J. M.A. LANGE, J. K.M.EEFTINCK SCHATTENKERK, C. H.N. VEENHOF

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Abstract. The effectiveness of addition of interferon‐alpha (IFN‐alpha) to zidovudine in patients with AIDS‐associated Kaposi's sarcoma was assessed in a non‐randomized, phase II clinical trial. Twenty‐one patients were treated with oral zidovudine (600 mg daily) and IFN‐alpha (9 MU subcutaneously daily) for 8 weeks. In patients with progressive disease, IFN‐alpha was increased to 18 MU daily for another 4 weeks. Only one of the 20 evaluable patients achieved a partial response at 8 weeks, that lasted for 3 months. Despite IFN‐alpha dose escalation in six patients, no further responses were seen. While myelotoxicity was mild, fatigue was the dose‐limiting side‐effect that prevented dose escalation in seven eligible patients. The combined treatment did not result in a decrease in HIV‐Ag. In summary, our results indicate that the addition of IFN‐alpha to zidovudine in patients with AIDS‐associated Kaposi's sarcoma is not an efficacious treatment. 1991 Blackwell Publishing Ltd

Original languageEnglish
Pages (from-to)35-40
Number of pages6
JournalJournal of Internal Medicine
Volume229
Issue number1
DOIs
Publication statusPublished - Jan 1991

Cite this